Exegenesis Bio and Modalis sign research deal for Duchenne therapy
Exegenesis Bio and Modalis Therapeutics have entered into a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for DMD.
Read the full article on the original site.
Read Full Article